insulin analog + pramlintide

**insulin analog + pramlintide** is a combination therapy in which a synthetic insulin analog (e.g., insulin lispro, insulin aspart, or insulin glargine) is administered together with **pramlintide**, an amylin analog. This regimen is used in people with diabetes (type 1 or type 2) who require intensified glycemic control and have not achieved target glucose levels on insulin therapy alone. **Insulin analogs** lower blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. **Pramlintide** mimics the hormone amylin, acting as an adjunct to insulin: it slows gastric emptying, suppresses postprandial glucagon secretion, and increases satiety, resulting in lower postprandial glucose excursions and, in some cases, mild weight loss. Both agents are typically delivered by subcutaneous injection immediately prior to meals but must not be mixed in the same syringe or injected at the same site. This approach provides a more physiological replacement of natural pancreatic hormones lost in diabetes; studies have demonstrated improved A1C, reduced postprandial glucose, and attenuated weight gain compared to insulin alone[2][3][7].